Secondary Pulmonary Hypertension Life Expectancy

Actelion Pharmaceuticals announces commercial availability of epoprostenol injection for the treatment of U.S. ... Actelion Pharmaceuticals, Inc. today announced the commercial availability of epoprostenol for injection, an improved formula that is stable at room temperature epoprostenol for the treatment of primary pulmonary hypertension and pulmonary hypertension associated with the spectrum of disease in scleroderma NYHA class III and IV patients.


Leave a Comment

* are Required fields

CommentLuv Enabled

This site uses KeywordLuv. Enter YourName@YourKeywords in the Name field to take advantage.



Powered by Yahoo! Answers